# Advancing the management of hard-to-heal wounds: a prospective, multicenter study of a next-generation multi-layered foam dressing

Russel Caprioli, DPM;<sup>1</sup> Cristin Taylor<sup>2</sup>

<sup>1</sup>Northwell Health, Lake Success, NY; <sup>2</sup>Convatec Ltd., Lexington, MA, USA

## Introduction

- Hard-to-heal wounds present a significant healthcare challenge, due to their complex etiology, impact on health-related quality of life, and large economic burden<sup>1</sup>
- The global prevalence of hard-to-heal wounds has been estimated as 2.21 per 1000 population and is predicted to increase with the ageing population<sup>2</sup>
- For the management of hard-to-heal wounds, guidelines recommend the use of a basic dressing that will provide a moisture-balanced wound healing environment, absorb excess wound exudate and protect the peri-wound skin; in addition to being cost-effective<sup>3,4</sup>

## **Study Objective**

To assess the efficacy and performance of next-generation advanced multi-layered foam dressings\* in the management of indicated hard-to-heal wounds.

Parameter

# Methods

- Prospective, multicenter, interventional, non-comparator, open-label (NCT05632250)
- Patients were recruited from seven sites. six in the United States and one in Chile
- Eligible wounds: venous leg ulcer, arterial leg ulcer, diabetic foot ulcer or pressure injury (stage 2 or higher) classified as hardto-heal for the purpose of this study (present for ≥30 days and ≤18 months)
- Dressings were applied according to the IFU and weekly in-clinic visits were conducted for up to 12 weeks
- Primary endpoint: to determine the percentage change in study wound area at 4 weeks
- Secondary endpoints:
- Satisfactory clinical progress (40%) reduction in study wound area at 4 weeks)
- Percent change in target wound area at 12 weeks
- Complete wound closure (100%) epithelialization of the wound surface)
- Safety: adverse events (AEs) and device related AEs

# Table 1. Baseline characteristics

Value

Patients, N	
Screened	92
Completed	73
Country, N Subjects (%)	
Chile	30 (32.61)
United States	62 (67.39)
Age, years	
Mean (SD)	65.99 (14.12)
Median	67.00
Q1, Q3	56.50, 76.00
Min, Max	27, 95
Age, years, N (%)	
< 65	42 (45.65)
65-79	35 (38.04)
80+	15 (16.30)
Sex, N Subjects (%)	
Female	32 (34.78)
Male	60 (65.22)
Study wound Type, N (%)	111 (100.00%)
Arterial Ulcer	3 (2.70)
Diabetic Ulcer	34 (30.63)
Pressure Injury	10 (9.01)
Venous Ulcer	64 (57.66)

## Results

#### **Patient characteristics**

- 92 patients (111 hard-to-heal wounds) were enrolled, 3 failed screening and 19 were discontinued from the study (Table 1)
- 73 patients with 109 hard-to-heal wounds completed the study
- Most patients presented with one wound (82.61%) with the most prevalent wound being venous ulcers (57.66%) followed by diabetic ulcers (30.63%; **Table 1**)
- A breakdown of the ConvaFoam™ dressing types utilized for each wound type are presented in **Figure 1**

Percentage change in wound area (n=109 wounds)

#### Week 4:

- Statistically significant median percentage change in wound area of -47.88% from baseline at week 4 (interquartile range (IQR) Q1, Q3: -73.53%, -17.33%; p<0.0001; **Figure 2**)
- Stratified by wound type: median percentage changes in wound area of 9.36% for arterial ulcers, -48.54% for diabetic ulcers, -33.51% for pressure injuries and -49.37% for venous ulcers were reported

#### Week 12:

- Statistically significant median percentage change in wound area of -93.75% from baseline at week 12 (IQR Q1, Q3: -100.00%, -44.44%; p<0.0001)
- Stratified by wound type: median percentage changes in wound area of -26.24% for arterial ulcers, -83.33% for diabetic ulcers, -85.95% for pressure injuries, and -99.48% for venous ulcers were reported

#### Satisfactory clinical progress (n=109 wounds)

- Sixty-one wounds (55.96%) experienced satisfactory clinical progress at week 4 (95% CI: 46.64%, 65.28%; p<0.0001; Figure 3)
- Stratified by wound type: one arterial ulcer (33.33%), 19 diabetic ulcers (57.58%), six pressure injuries (60.00%) and 37 venous ulcers (58.7%) achieved satisfactory clinical progress by week 4

### Complete wound closure (n=109 wounds)

- Forty-three wounds (39.45%) experienced complete wound closure by week 12 (95% CI, 30.27%, 48.62%; p<0.0001; Figure 4)
- Stratified by wound type: one arterial ulcer (33.33%), 12 diabetic ulcers (36.63%), two pressure injuries (20.00%), and 28 venous ulcers (44.44%) achieved complete wound closure by week 12

#### Safety

- There were two AEs related to the study dressings in the 2,935 dressing applications
- One skin tear and one periwound skin irritation

## Figure 2. Median percentage change in wound area at 4 weeks




Figure 3. Percentage of wounds that demonstrated satisfactory clinical progress at 4 weeks






Figure 4. Percentage of wounds that experienced complete wound closure



## Figure 1. Dressing utilization by wound type



# Discussion

- Hard-to-heal wounds treated with the next-generation multilayered foam dressings\* were associated with clinical progression of wound healing, demonstrating a statistically significant median percentage area reduction of 48% at 4 weeks
- The dressings were shown to be safe, with only two dressing related-AEs reported out of 2,935 dressing applications
- Despite the broad population of the patients included in the study, the results were favorable and can be generalized to real world clinical practice

## Conclusion

The next-generation advanced multi-layered foam dressings\* were shown to be safe and effective in the management of hard-to-heal wounds

# References

1. Rice JB et al. Diabetes Care 2014;37(3):651–658; 2. Martinengo L et al. Ann Epidemiol 2019;29:8-15; 3. Schaper NC, et al. Diabetes Metab Res Rev 2024;40:e3657; 4. Lavery LA, et al. Wound Repair Regen 2024;32:34-46.

\*ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-adhesive